AptarGroup (ATR) Bank of America 2026 Global Agriculture and Materials Conference summary

Key business highlights

• Proprietary drug delivery systems, especially nasal, are a core strength and expanding into new therapeutic areas beyond allergies, including GLP-1, neurodegenerative, and cardiovascular diseases.

• Recognized as a global leader in drug and consumer product dosing, dispensing, and protection technologies, with a diversified portfolio spanning pharma, beauty, closures, and food markets.

• Consumer-facing businesses, including closures and beauty, have improved, with closures returning to target range and beauty resuming growth despite operational hiccups.

• Sustainability leadership in consumer business is increasingly relevant for healthcare, and the global supply chain is structured to manage regional trade tensions.

• The company is comfortable with its Q1 guidance and expects a good quarter, with emergency medicine (naloxone) as the main exception.

Strategic positioning and innovation

• Maintains a robust innovation pipeline with over 7,000 active and pending patents, and invests approximately 3% of sales in R&D, primarily focused on pharma.

• Proprietary drug delivery systems and advanced dispensing solutions provide a competitive edge, supported by regulatory expertise and high reliability.

• Consistently acknowledged for sustainability leadership, earning top industry recognitions for ESG and climate initiatives.

• Strong balance sheet and disciplined capital allocation, with a long-term leverage target of 1-3x and significant returns to shareholders through dividends and buybacks.

• Focused on maximizing user satisfaction and safety through human factors expertise and rapid innovation cycles.

Financial performance and segment results

• Achieved total reported sales of $3.78B in 2025, with 5% overall growth; pharma led with $1.74B (6% growth), beauty at $1.31B (7% growth), and closures at $730M (2% growth).

• Pharma segment delivered 3% core sales growth, driven by emergency medicine, CNS solutions, and injectables, with a 35% adjusted EBITDA margin.

• Beauty segment saw 2% core sales growth, with strong personal care demand offsetting declines in fragrance and skincare; adjusted EBITDA margin at 12.1%.

• Closures segment posted 1% core sales growth, with food and beverage outperforming, and a 16% adjusted EBITDA margin.

• Approximately two-thirds of capital was reinvested into core operations and growth, while one-third was returned to shareholders.